Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Linong JiJianhua MaWeiping LuJingdong LiuJiao'e ZengJialin YangWei LiXiuzhen ZhangXinhua XiaoGen TakayanagiYi WangPublished in: Journal of diabetes investigation (2020)
At 24 weeks, teneligliptin was generally well tolerated and effective in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.